Drug Profile
BMS 986218
Alternative Names: Anti-CTLA-4 NF - Bristol-Myers Squibb; BMS-986218Latest Information Update: 29 Dec 2023
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb
- Developer Bristol-Myers Squibb; Columbia University; Ferring Pharmaceuticals
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T-lymphocyte antigen 4 inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Prostate cancer; Solid tumours
Most Recent Events
- 06 Dec 2023 Bristol-Myers Squibb completes a phase II trial in Prostate cancer (Hormone refractory, Metastatic disease, Combination therapy, Second-line therapy or greater) in USA, United Kingdom, Netherlands, Italy, Greece, France, Canada, Argentina (Parenteral) (NCT05169684)
- 28 Mar 2023 No recent reports of development identified for phase-I development in Prostate-cancer(Combination therapy, Neoadjuvant therapy) in USA (IV)
- 27 Dec 2021 Bristol-Myers Squibb plans a phase II trial for Prostate cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in USA, France, Greece, Netherlands (NCT05169684)